Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

Davita Healthcare Partners / Equity Bottom-Up

<ul><li>The second quarter 2026 results of DaVita Inc., a provider of dialysis services and related healthcare solutions, largely aligned with company expectations, reflecting continued momentum in patient outcomes and financial performance.</li><li>Treatment volume growth in U.S. dialysis accelerated slightly more than anticipated, primarily driven by improved patient mortality rates, though new patient admissions and missed treatments remained largely in line with prior guidance.</li><li>Revenue per treatment declined sequentially by about $2 due to a decrease in commercial payer mix related to lower Affordable Care Act enrollment and reduced revenue from phosphate binders following their integration into the Medicare dialysis bundle.</li></ul>

The second quarter 2026 results of DaVita Inc., a provider of dialysis services and related healthcare solutions, largely aligned with company expectations, reflecting continued momentum in patient outcomes and financial performance.Treatment volume growth in U.S. dialysis accelerated slightly more than anticipated, primarily driven by improved patient mortality rates, though new patient admissions and missed treatments remained largely in line with prior guidance.Revenue per treatment declined sequentially by about $2 due to a decrease in commercial payer mix related to lower Affordable Care Act enrollment and reduced revenue from phosphate binders following their integration into the Medicare dialysis bundle.

DaVita Is Not Just A Dialysis Story — Integrated Kidney Care Is Gaining Momentum!

Smartkarma AI Primers, Smartkarma

αSK Primers

Smartkarma AI Primers

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

<ul>
 <li>DaVita is a market leader in the U.S. dialysis duopoly, generating stable, recurring revenue from essential kidney care services, with a growing focus on integrated, value-based care models.</li>
 <li>The company's financial performance is characterized by strong free cash flow generation and improving margins, though it is highly dependent on government reimbursement rates, particularly from Medicare, which presents a significant risk.</li>
 <li>Future growth is expected to be driven by the rising prevalence of kidney disease, expansion of home dialysis programs, and the strategic shift towards integrated care, which aims to manage patient health more holistically and reduce overall healthcare costs.</li>
</ul>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


  DaVita is a market leader in the U.S. dialysis duopoly, generating stable, recurring revenue from essential kidney care services, with a growing focus on integrated, value-based care models.
  The company's financial performance is characterized by strong free cash flow generation and improving margins, though it is highly dependent on government reimbursement rates, particularly from Medicare, which presents a significant risk.
  Future growth is expected to be driven by the rising prevalence of kidney disease, expansion of home dialysis programs, and the strategic shift towards integrated care, which aims to manage patient health more holistically and reduce overall healthcare costs.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Primer: Davita Healthcare Partners (DVA US) - Aug 2026

<ul>
 <li>
<a href="https://smartkarma.com/entities/davita-inc">DaVita </a>stands as a market leader in the U.S. dialysis services industry, a sector characterized by non-discretionary, recurring demand driven by demographic tailwinds such as an aging population and a rising prevalence of chronic kidney disease.</li>
 <li>The company's business model is highly dependent on government reimbursement, with a majority of its revenue tied to Medicare and Medicaid rates, creating significant regulatory and policy-related risk.</li>
 <li>Strategic initiatives are focused on expanding integrated kidney care (IKC) and value-based care models, which aim to improve patient outcomes and lower overall healthcare costs, positioning <a href="https://smartkarma.com/entities/davita-inc">DaVita </a>for shifts in healthcare payment systems.</li>
</ul>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


  
DaVita stands as a market leader in the U.S. dialysis services industry, a sector characterized by non-discretionary, recurring demand driven by demographic tailwinds such as an aging population and a rising prevalence of chronic kidney disease.
  The company's business model is highly dependent on government reimbursement, with a majority of its revenue tied to Medicare and Medicaid rates, creating significant regulatory and policy-related risk.
  Strategic initiatives are focused on expanding integrated kidney care (IKC) and value-based care models, which aim to improve patient outcomes and lower overall healthcare costs, positioning DaVita for shifts in healthcare payment systems.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Index Rebalance and Special Situations Coverage, Quiddity Advisors

Anjana Amarasuriya

Index Rebalance and Special Situations Coverage

Quiddity Advisors

Pan-Asia Catalysts/Events

Index Rebalance

<ul>
<li>The SP 500 index tracks the 500 largest names listed in the US and it is one of the most highly-tracked indices in the world.</li>
<li>In this insight, we have presented our expectations for ADDs and DELs for the upcoming quarterly review in March 2026.</li>
<li>We expect one intra-review index change before the regular rebalance and two changes during the March 2026 regular rebalance. There is an SP 400 intra-review change this week.</li>
</ul>


The SP 500 index tracks the 500 largest names listed in the US and it is one of the most highly-tracked indices in the world.
In this insight, we have presented our expectations for ADDs and DELs for the upcoming quarterly review in March 2026.
We expect one intra-review index change before the regular rebalance and two changes during the March 2026 regular rebalance. There is an SP 400 intra-review change this week.


Quiddity Leaderboard SP500/600 Mar26 Rebal: TWO Regular ADDs/DELs + ONE Intra-Review Change Coming

<ul><li>The report on DaVita Inc.’s first quarter of 2026 presents a mixture of advancements and challenges, reflecting a cautious yet optimistic operational outlook.</li><li>The company emphasizes its commitment to clinical excellence and continued investments in digital infrastructure to support evolving healthcare needs.</li><li>Notably, its Integrated Kidney Care (IKC) value-based care business demonstrated measurable progress in the Centers for Medicare & Medicaid Services (CMS) Comprehensive Kidney Care Contracting program, showing improvements in gross savings rates, quality scores, and maintaining high-performing status.</li></ul>

The report on DaVita Inc.’s first quarter of 2026 presents a mixture of advancements and challenges, reflecting a cautious yet optimistic operational outlook.The company emphasizes its commitment to clinical excellence and continued investments in digital infrastructure to support evolving healthcare needs.Notably, its Integrated Kidney Care (IKC) value-based care business demonstrated measurable progress in the Centers for Medicare & Medicaid Services (CMS) Comprehensive Kidney Care Contracting program, showing improvements in gross savings rates, quality scores, and maintaining high-performing status.

DaVita: Building a High-Performance Kidney Care Model Through Clinical Excellence and Cost Discipline!

United States

DaVita Inc. provides a variety of health care services. The Company provides kidney dialysis services for patients suffering from chronic kidney failure. DaVita serves patients worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Davita Healthcare Partners (DVA US)

DaVita Is Not Just A Dialysis Story — Integrated Kidney Care Is Gaining Momentum!

The second quarter 2026 results of DaVita Inc., a provider of dialysis services and related healthcare solutions, largely aligned with company...

Baptista Research

Primer: Davita Healthcare Partners (DVA US) - Aug 2026

DaVita is a market leader in the U.S. dialysis duopoly, generating stable, recurring revenue from essential kidney care services, with a growing...

αSK Primers

Primer: DaVita (DVA UN) - Aug 2026

DaVita stands as a market leader in the U.S. dialysis services industry, a sector characterized by non-discretionary, recurring demand driven...

αSK Primers

Quiddity Leaderboard SP500/600 Mar26 Rebal: TWO Regular ADDs/DELs + ONE Intra-Review Change Coming

There are now 19 Intra-review changes (25 flow lines) for SP 400, SP 600, and SP Completion and a couple of index upweights for SP 500. Over US$4...

Anjana Amarasuriya

DaVita: Building a High-Performance Kidney Care Model Through Clinical Excellence and Cost Discipline!

The report on DaVita Inc.’s first quarter of 2026 presents a mixture of advancements and challenges, reflecting a cautious yet optimistic...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)